This study examined effects of intracerebroventricularly (i.c.v.) administered somatostatin (SRIH-14 and SRIH-28) on growth and function of pituitary somatotropes (GH cells) and lactotropes (PRL cells). Male rats received three i.c.v. injections (1 µg/5 µl) of SRIH-14 or SRIH-28 every second day. Blood samples were collected for hormone assays and pituitaries were removed for histological and morphometric evaluation 5 days after the last i.c.v. treatment. Compared to control animals, SRIH treatment decreased (p < 0.05) pituitary weight and all morphometric measurements obtained in GH and PRL cells. Concentrations of serum growth hormone (GH) and prolactin (PRL) in both SRIH-treated groups were also lower (p < 0.05) than in control rats. These findings suggest that centrally administered somatostatin is specifically involved in the control of growth and secretory activity of GH and PRL cells. Thus, pharmacological manipulation of SRIH receptors reached from cerebrospinal fluid may alter systemic effects of GH and PRL.

This study examined the effects of intracerebroventricularly administered somatostatin (SRIF-28 and SRIF-14) on growth and steroidogenic capacity of the rat adrenal zona glomerulosa. Male adult Wistar rats were subjected to intracerebroventricular administration of three 1 µg doses of SRIF-28 or SRIF-14 every other day. Five days after the last dose, the rats were sacrificed by decapitation. Blood samples were collected for hormonal analyses, and left adrenal glands were taken for histological and morphometric evaluation. In comparison with control animals, the SRIF-treated rats had decreased (p < 0.05) adrenal gland weight and volume. Stereological and morphometric analyses showed decreased (p < 0.05) absolute and relative volumes of the cells and nuclei only in the zona glomerulosa. The plasma levels of aldosterone, growth hormone, and prolactin in both SRIF-treated groups were lower (p < 0.05) than in the control group. The levels of adrenocorticotropic hormone after SRIF treatment did not differ significantly from those in control rats. These findings suggest that centrally administered somatostatin is specifically involved in the control of zona glomerulosa growth and secretion; this effect is probably mediated by inhibiting the secretion of the corresponding pituitary hormones.